Compound: aplaviroc
SMILES: O=C1N[C@@H](C(=O)N(C12CCN(Cc3ccc(Oc4ccc(C(=O)O)cc4)cc3)CC2)CCCC)[C@H](O)C5CCCCC5
InChIKey: GWNOTCOIYUNTQP-FQLXRVMXSA-N
Synonyms: aplaviroc, 461443-59-4, GW873140, AK-602, GW 873140, GW-873140, AK602, 98B425P30V, GSK-873140, DTXSID6047317, Benzoic acid, 4-(4-(((3R)-1-butyl-3-((R)-cyclohexylhydroxymethyl)-2,5-dioxo-1,4,9-triazaspiro(55)undec-9-yl)methyl)phenoxy)-, 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid, aplavirocum, 4-(4-(((3R)-1-butyl-3-((R)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro(5.5)undecan-9-yl)methyl)phenoxy)benzoic acid, 4-(4-(((3R)-1-butyl-3-((R)-cyclohexyl-hydroxymethyl)-2,5-dioxo-1,4,9-triazaspiro(5.5)undecan-9-yl)methyl)phenoxy)benzoic acid, 4-[4-({(3R)-1-Butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl}methyl)phenoxy]benzoic acid, 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl-hydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid, RefChem:113420, DTXCID4027317, GSK-87314, 4-(4-(((3R)-1-butyl-3-((R)-cyclohexylhydroxymethyl)-2,5-dioxo-1,4,9-triazaspiro(5.5)undecan-9-yl)methyl)phenoxy)benzoic acid, Aplaviroc [INN], AK 602, 4-[4-[[(9R)-11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid, CHEMBL1668019, 4-(4-(((R)-1-Butyl-3-((R)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl)methyl)phenoxy)benzoic acid, ONO 4128, UNII-98B425P30V, PG9-apl conjugate, GSK873140, CD4-IgG-apl conjugate, mAB b12-apl conjugate, APLAVIROC [MI], AK 602;GSK 873140;GW 873140, mAb 2G12-apl conjugate, mAB PG16-apl conjugate, APLAVIROC [WHO-DD], CD4-IgG aplaviroc conjugate, mAB PG9-aplaviroc conjugate, GTPL805, Trastuzumab-aplaviroc conjugate, orb1707646, SCHEMBL4577096, CHEMBL1255794, b12 antibody-aplaviroc conjugate, PG16 antibody-aplaviroc conjugate, 2G12 antibody-aplaviroc conjugate, BDBM50336345, AKOS040741156, DB06497, NCGC00247933-01, 4-((4-(((3R)-1-butyl-3-((R)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro(5.5)undec-9-yl)methyl)phenyl)oxy)benzoic acid hydrochloride, AC-31372, BA166505, DA-61166, HY-17450, CS-0008289, Trastuzumab antibody conjugated with aplaviroc, Q4779956, 4-(4-(((R)-1-butyl-3-((R)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl)methyl)phenoxy)benzoic acid hydrochloride, 674782-28-6, Benzoic acid, 4-[4-[[1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-, Benzoic acid, 4-[4-[[1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- & Soluble CD4
Theoretical properties:
molecular_formula: C33H43N3O6
molecular_weight: 577.7 g/mol
exact_mass: 577.31518610 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 3
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 10
heavy_atom_count: 42
topological_polar_surface_area: 119 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
chembl: APLAVIROC is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline.
In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations.